Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLCG1 | P19174 | 2/20 | 0.45 |
| ▸ | TEK | Q02763 | 3/20 | 0.43 |
| ▸ | TGM2 | P21980 | 2/20 | 0.43 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.42 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.41 |
| ▸ | MAP2K7 | O14733 | 2/20 | 0.40 |
| ▸ | BTK | Q06187 | 2/20 | 0.39 |
| ▸ | EGFR | P00533 | 4/20 | 0.39 |
| ▸ | JAK3 | P52333 | 1/20 | 0.38 |
| ▸ | PPARG | P37231 | 1/20 | 0.38 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.37 |
| ▸ | ITK | Q08881 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24150847 | 0.85 | CDK7 (0.46) | PLCG1TEKMAP4K4BTKEGFR | |
| SCHEMBL24150349 | 0.84 | PLCG1 (0.60) | PLCG1TGM2MAP2K7BTKEGFR | |
| SCHEMBL30190893 | 0.81 | TEK (0.50) | TEKTGM2EPHB4KDRMAP4K4 | |
| SCHEMBL24150851 | 0.81 | TEK (0.50) | TEKTGM2EPHB4KDRMAP4K4 | |
| SCHEMBL30190618 | 0.80 | MAP4K4 (0.44) | TEKTGM2KDRMAP4K4BTK | |
| SCHEMBL24150841 | 0.80 | MAP4K4 (0.44) | TEKTGM2KDRMAP4K4BTK | |
| SCHEMBL24150228 | 0.79 | MAP4K4 (0.42) | PLCG1TEKTGM2KDRMAP4K4 | |
| SCHEMBL24151340 | 0.78 | PLCG1 (0.48) | PLCG1MAP2K7BTKEGFRJAK3 | |
| SCHEMBL24150234 | 0.78 | BTK (0.41) | TEKTGM2EPHB4KDRMAP4K4 | |
| SCHEMBL30191027 | 0.78 | BTK (0.41) | TEKTGM2EPHB4KDRMAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11926632-B2 | Methods and compounds for restoring mutant p53 function | PMV PHARMACEUTICALS, INC. (US) | 2024-03-12 | — | — | US | disclosed |
| US-20230046427-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | PMV PHARMACEUTICALS, INC. | 2023-02-16 | — | — | US | disclosed |
| US-20230046427-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | PMV PHARMACEUTICALS, INC. | 2023-02-16 | — | — | US | disclosed |
| WO-2021262596-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT P53 FUNCTION | PMV PHARMACEUTICALS, INC. (US) | 2021-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230046427-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | TP53, TP53BP1, HRAS | PLCG1 2034/4885TEK 4357/4885TGM2 1814/4885 |
| US-11926632-B2 | Methods and compounds for restoring mutant p53 function | TP53, TP53BP1, HRAS | PLCG1 2034/4885TEK 4357/4885TGM2 1814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.